DGIdb - LANSOPRAZOLE Drug Record

LANSOPRAZOLE chembl:CHEMBL480 Approved

Alternate Names:

PREVACID
AG-1749
PREVACID DELAYED RELEASE
OPIREN
PREVACID 24HR
PREVACID SOLUTAB
LANSOPRAZOLE
PREVACID IV
A-65006
ZOTON
LIMPIDEX
MONOLITUM
LANZOL
OGASTRO
AG 1749
LANZUL
PREVACID (TN)
LANZOPRAL
LANSOPRAZOLUM
PREVACID®
LANSOPRAZOL
BAMALITE
pubchem.compound:3883
rxcui:17128
chemidplus:103577-45-3
chembl:CHEMBL480
drugbank:00448

Drug Info:

Drug Class	gi anti-ulcer agents, proton-pump inhibitors
Year of Approval	1995
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antiulcer agent

(4 More Sources)

Publications:

Zhang L et al., 2010, The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people., J Clin Pharm Ther
Sugimoto et al., 2006, Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy., Clin. Pharmacol. Ther.
Take S et al., 2003, Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection., Am J Gastroenterol
Langtry et al., 1997, Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders., Drugs
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Matheson et al., 2001, Lansoprazole: an update of its place in the management of acid-related disorders., Drugs
Miura M et al., 2006, Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus., Int J Clin Pharmacol Ther
Yoshinari K et al., 2008, Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements., Biochem Pharmacol
Handa et al., 2006, Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors., Inflamm. Res.
Rojo LE et al., 2010, Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease., J Alzheimers Dis
González et al., Anaphylaxis to proton pump inhibitors., Allergol Immunopathol (Madr)
Agnihotri et al., Role of oxidative stress in lansoprazole-mediated gastric and hepatic protection in Wistar rats., Indian J Gastroenterol
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Daujat et al., 1996, Induction of CYP1A1 gene by benzimidazole derivatives during Caco-2 cell differentiation. Evidence for an aryl-hydrocarbon receptor-mediated mechanism., Eur. J. Biochem.

LANSOPRAZOLE TPSD1

Interaction Score: 2.38

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12464168

Sources:
NCI
LANSOPRAZOLE PHOSPHO1

Interaction Score: 1.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LANSOPRAZOLE ATP4A

Interaction Score: 1.02

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Potassium-transporting ATPase inhibitor

Direct Interaction yes

Trial Name lansoprazole , AG 1749,Prevacid, Takepron

PMIDs:
9279507 11752352 11693467

Sources:
TdgClinicalTrial ChemblInteractions TEND
LANSOPRAZOLE IL1B

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21054464 16815316 14638340

Sources:
NCI PharmGKB
LANSOPRAZOLE GSR

Interaction Score: 0.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17704577

Sources:
NCI
LANSOPRAZOLE ATP4B

Interaction Score: 0.24

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Potassium-transporting ATPase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
LANSOPRAZOLE CYP1A1

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8647108

Sources:
NCI
LANSOPRAZOLE CXCL8

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17122965

Sources:
NCI
LANSOPRAZOLE CYP3A5

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
LANSOPRAZOLE RGS4

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LANSOPRAZOLE NR1I2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
LANSOPRAZOLE ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17190370

Sources:
PharmGKB
LANSOPRAZOLE NPC1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LANSOPRAZOLE RAB9A

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LANSOPRAZOLE ALOX15

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LANSOPRAZOLE PLK1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LANSOPRAZOLE MAPT

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20110603

Sources:
DTC
LANSOPRAZOLE CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC FDA
LANSOPRAZOLE CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18502397

Sources:
PharmGKB
LANSOPRAZOLE KDM4E

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LANSOPRAZOLE BAZ2B

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LANSOPRAZOLE VDR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LANSOPRAZOLE CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LANSOPRAZOLE NFE2L2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LANSOPRAZOLE EHMT2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
LANSOPRAZOLE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: LANSOPRAZOLE
- Version: 01-August-2011
Alternate Names:

LANSOPRAZOLE Primary Drug Name

Drug Info:

Year of Approval 1995

Drug Class gi anti-ulcer agents, proton-pump inhibitors

Publications:
TdgClinicalTrial: LANSOPRAZOLE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antiulcer agent

Drug Class Small Molecule

FDA Approval approved

Publications:

NCI: LANSOPRAZOLE

Version: 14-September-2017

Alternate Names:

C29150 NCI drug code

Drug Info:

Publications:

Sugimoto et al., 2006, Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy., Clin. Pharmacol. Ther.

Agnihotri et al., Role of oxidative stress in lansoprazole-mediated gastric and hepatic protection in Wistar rats., Indian J Gastroenterol

Handa et al., 2006, Molecular mechanisms involved in anti-inflammatory effects of proton pump inhibitors., Inflamm. Res.

PharmGKB: lansoprazole

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Sugimoto et al., 2006, Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy., Clin. Pharmacol. Ther.

Zhang L et al., 2010, The effect of cytochrome P2C19 and interleukin-1 polymorphisms on H. pylori eradication rate of 1-week triple therapy with omeprazole or rabeprazole, amoxycillin and clarithromycin in Chinese people., J Clin Pharm Ther

Take S et al., 2003, Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection., Am J Gastroenterol

DTC: LANSOPRAZOLE
- Version: 02-September-2020
Alternate Names:

CHEMBL480 ChEMBL Drug ID

Drug Info:

Publications:
FDA: Lansoprazole
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL480
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL480
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Mechanism of Interaction	Potassium-transporting ATPase inhibitor
Direct Interaction	yes
Trial Name	lansoprazole , AG 1749,Prevacid, Takepron

LANSOPRAZOLE Drug Record

LANSOPRAZOLE chembl:CHEMBL480 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12464168

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Potassium-transporting ATPase inhibitor Direct Interaction yes Trial Name lansoprazole , AG 1749,Prevacid, Takepron

PMIDs: 9279507 11752352 11693467

Sources: TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21054464 16815316 14638340

Sources: NCI PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17704577

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Mechanism of Interaction Potassium-transporting ATPase inhibitor Direct Interaction yes

PMIDs: None found

Sources: ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8647108

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17122965

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17190370

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20110603

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18502397

Interaction Types & Directionality:

n/a

PMIDs:
12464168

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Potassium-transporting ATPase inhibitor

Direct Interaction yes

Trial Name lansoprazole , AG 1749,Prevacid, Takepron

PMIDs:
9279507 11752352 11693467

Sources:
TdgClinicalTrial ChemblInteractions TEND

Interaction Types & Directionality:

n/a

PMIDs:
21054464 16815316 14638340

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17704577

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Potassium-transporting ATPase inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
8647108

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17122965

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17190370

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
20110603

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC FDA

Interaction Types & Directionality:

n/a

PMIDs:
18502397

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC